Viridian Therapeutics (VRDN)

• Market cap: $1.53B
• 1 day: -2.8%
• 5 days: -19.19%
• 1 month: -48.78%
• 3 months: -54.1%
• 6 months: -28.78%
• Year to date: -51.27%
• 1 year: 31.03%
• 5 years: -4.96%
• 10 years: -85.23%
• Sector: Healthcare
• Industry: Biotechnology

About: Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. The company is developing two anti-IGF-1R product candidates, veligrotug for intravenous (IV) administration and elegrobart (formerly VRDN-003) for subcutaneous (SC) administration, to treat patients with TED. Our most advance program, veligrotug, is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of TED.

Employees: 252